Method for determining the sensitivity of patients suffering from a cancer disease to biological therapy
AssigneesUniverzita Palackeho V Olomouci, Lekarska Fakulta, Masarykuv Onkologicky Ustav
InventorsMarian Hajduch, Marta Dziechciarkova, Lenka Radova, Marek Svoboda
Life of this patent
Estimating the term…
Abstract
The invention relates to a method for determining the sensitivity of patients suffering from a cancer disease towards targeted biological therapy based on the inhibition of signaling pathways of the members of HER family (e.g., HER-1, HER-2, HER-3 and HER-4) by determining the expression of the biomarker S6 kinase or its post-translationally modified form or of the biomarkers of the activation of S6 kinase or their post-translationally modified forms in the tumor.
Claims1
A method for determining the sensitivity of a breast cancer patient to trastuzumab therapy comprising:
- (a) obtaining a breast tumor tissue sample;
- (b) measuring the level of S6Kinase 1 (S6K1) protein or the level of S6K1 phosphorylation at Serine235/236 in the sample;
- and
- (c) identifying the patient as sensitive to trastuzumab therapy when the sample is negative for S6K1 protein expression or phosphorylation at Serine235/236, and
- identifying the patient as resistant to trastuzumab therapy when the sample is positive for S6K1 protein expression or phosphorylation at Serine235/236.
Dependencies are inferred from the claim text.